{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T05:51:09Z","timestamp":1648965069088},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00347-011-2504-9","type":"journal-article","created":{"date-parts":[[2012,6,14]],"date-time":"2012-06-14T08:47:09Z","timestamp":1339663629000},"page":"568-574","source":"Crossref","is-referenced-by-count":2,"title":["Therapie des Morbus Beh\u00e7et gestern und heute"],"prefix":"10.1007","volume":"109","author":[{"given":"C.M.E.","family":"Deuter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zierhut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Doycheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,16]]},"reference":[{"key":"2504_CR1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61\u201370","journal-title":"Semin Arthritis Rheum"},{"key":"2504_CR2","first-page":"136","volume":"20","author":"BenEzra","year":"1988","unstructured":"BenEzra D, Cohen E, Chajek T et al (1988) Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et\u2019s syndrome. Transplant Proc 20:136\u2013143","journal-title":"Transplant Proc"},{"key":"2504_CR3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","volume":"15","author":"Buggage","year":"2007","unstructured":"Buggage RR, Levy-Clarke G, Sen HN et al (2007) A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Beh\u00e7et\u2019s disease. Ocul Immunol Inflamm 15:63\u201370","journal-title":"Ocul Immunol Inflamm"},{"key":"2504_CR4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.preteyeres.2007.09.002","volume":"27","author":"Deuter","year":"2008","unstructured":"Deuter CME, K\u00f6tter I, Wallace GR et al (2008) Beh\u00e7et\u2019s disease: ocular effects and treatment. Prog Retin Eye Res 27:111\u2013136","journal-title":"Prog Retin Eye Res"},{"key":"2504_CR5","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"Deuter","year":"2010","unstructured":"Deuter CME, Zierhut M, M\u00f6hle A et al (2010) Long-term remissions after cessation of interferon alpha treatment in patients with severe uveitis due to Beh\u00e7et\u2019s disease. Arthritis Rheum 62:2796\u20132805","journal-title":"Arthritis Rheum"},{"key":"2504_CR6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","volume":"146","author":"Gueudry","year":"2008","unstructured":"Gueudry J, Wechsler B, Terrada C et al (2008) Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Beh\u00e7et disease. Am J Ophthalmol 146:837\u2013844","journal-title":"Am J Ophthalmol"},{"key":"2504_CR7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"G\u00fcl","year":"2012","unstructured":"G\u00fcl A, Tugal-Tutkun I, Dinarello CA et al (2012) Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Beh\u00e7et\u2019s disease: an open-label pilot study. Ann Rheum Dis 71:563\u2013566","journal-title":"Ann Rheum Dis"},{"key":"2504_CR8","doi-asserted-by":"crossref","unstructured":"Hamuryudan V, K\u00f6tter I (2010) Medical management of Beh\u00e7et\u2019s syndrome. In: Yazici Y, Yazici H (Hrsg) Beh\u00e7et\u2019s syndrome. Springer, Berlin Heidelberg New York Tokyo, S\u00a0317\u2013338","DOI":"10.1007\/978-1-4419-5641-5_19"},{"key":"2504_CR9","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis 67:1656\u20131662","journal-title":"Ann Rheum Dis"},{"key":"2504_CR10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","volume":"25","author":"K\u00f6tter","year":"2006","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Batra M et al (2006) CNS involvement occurs more frequently in patients with Beh\u00e7et\u2019s disease under cyclosporin A (CSA) than under other medications \u2013 results of a retrospective analysis of 117 cases. Clin Rheumatol 25:482\u2013486","journal-title":"Clin Rheumatol"},{"key":"2504_CR11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","volume":"33","author":"K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Zierhut M, St\u00fcbiger N (2004) The use of interferon \u03b1 in Beh\u00e7et disease: review of the literature. Semin Arthritis Rheum 33:320\u2013335","journal-title":"Semin Arthritis Rheum"},{"key":"2504_CR12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"K\u00f6tter","year":"2003","unstructured":"K\u00f6tter I, Zierhut M, Eckstein AK et al (2003) Human recombinant interferon alfa-2a for the treatment of Beh\u00e7et\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423\u2013431","journal-title":"Br J Ophthalmol"},{"key":"2504_CR13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","volume":"106","author":"Kotake","year":"1999","unstructured":"Kotake S, Higashi K, Yoshikawa K et al (1999) Central nervous system symptoms in patients with Beh\u00e7et disease receiving cyclosporine therapy. Ophthalmology 106:586\u2013589","journal-title":"Ophthalmology"},{"key":"2504_CR14","first-page":"896","volume":"35","author":"Krause","year":"2008","unstructured":"Krause L, Altenburg A, Pleyer U et al (2008) Longterm visual prognosis of patients with ocular Adamantiades-Beh\u00e7et\u2019s disease treated with interferon-\u03b1-2a. J Rheumatol 35:896\u2013903","journal-title":"J Rheumatol"},{"key":"2504_CR15","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","volume":"1","author":"Masuda","year":"1989","unstructured":"Masuda K, Nakajima A, Urayama A et al (1989) Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporin in Beh\u00e7et\u2019s disease. Lancet 1:1093\u20131096","journal-title":"Lancet"},{"key":"2504_CR16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","volume":"76","author":"Ozyazgan","year":"1992","unstructured":"Ozyazgan Y, Yurdakul S, Yazici H et al (1992) Low dose cyclosporine A versus pulsed cyclophosphamide in Beh\u00e7et\u2019s syndrome: a single masked trial. Br J Ophthalmol 76:241\u2013243","journal-title":"Br J Ophthalmol"},{"key":"2504_CR17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s10165-008-0057-9","volume":"18","author":"Saddredini","year":"2008","unstructured":"Saddredini S, Noshad H, Molaeefard M, Noshad R (2008) Treatment of retinal vasculitis in Beh\u00e7et\u2019s disease with rituximab. Mod Rheumatol 18:306\u2013308","journal-title":"Mod Rheumatol"},{"key":"2504_CR18","doi-asserted-by":"crossref","unstructured":"Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Beh\u00e7et\u2019s disease \u2013 review and basis for ecommendations. Rheumatology (Oxford) 46:736\u2013741","DOI":"10.1093\/rheumatology\/kem034"},{"key":"2504_CR19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG et al (2001) Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease. Lancet 358:295\u2013296","journal-title":"Lancet"},{"key":"2504_CR20","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","volume":"117","author":"Sobaci","year":"2010","unstructured":"Sobaci G, Erdem U, Durukan AH et al (2010) Safety and effectiveness of interferon alpha-2a in treatment of patients with Beh\u00e7et\u2019s uveitis refractory to conventional treatments. Ophthalmology 117:1430\u20131435","journal-title":"Ophthalmology"},{"key":"2504_CR21","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease. Arthritis Rheum 52:2478\u20132484","journal-title":"Arthritis Rheum"},{"key":"2504_CR22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","volume":"94","author":"Yamada","year":"2010","unstructured":"Yamada Y, Sugita S, Tanaka H et al (2010) Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease. Br J Ophthalmol 94:284\u2013288","journal-title":"Br J Ophthalmol"},{"key":"2504_CR23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000060761","volume":"31","author":"Yazici","year":"1999","unstructured":"Yazici H, Ozyagan Y (1999) Medical management of Beh\u00e7et\u2019s syndrome. Dev Ophthalmol 31:118\u2013131","journal-title":"Dev Ophthalmol"},{"key":"2504_CR24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome. N Engl J Med 322:281\u2013285","journal-title":"N Engl J Med"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-011-2504-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-011-2504-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-011-2504-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T20:23:32Z","timestamp":1561839812000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-011-2504-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["2504"],"URL":"https:\/\/doi.org\/10.1007\/s00347-011-2504-9","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}